STAT Plus: Pharmalittle: An ALS drug may become available under ‘right to try’; Takeda shareholders look to derail Shire deal

A group of Takeda Pharmaceutical shareholders is building support to block the $62 billion acquisition of Shire at an extraordinary general meeting

More From BioPortfolio on "STAT Plus: Pharmalittle: An ALS drug may become available under ‘right to try’; Takeda shareholders look to derail Shire deal"